H

Hospital Sultanah Bahiyah | Clinical Research Centre

Research site
(Unclaimed)
Location
Clinical Research Centre (CRC) Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia

Site insights

Top conditions

Top treatments

Upadacitinib
ABT-494
Relamorelin
Ziltivekimab
Semaglutide
JNJ-56136379
Apixaban
Luspatercept
Trimethoprim
Pelabresib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

16 of 45 total trials

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes (SOUL)

The researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease. Participants...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Placebo (semaglutide)

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Upadacitinib
Drug: Upadacitinib

The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either...

Enrolling
Systemic Inflammation
Heart Failure
Drug: Placebo
Drug: Ziltivekimab
Locations recently updated

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling
Heart Failure
Drug: Placebo
Drug: Ziltivekimab

The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 dia...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Placebo (semaglutide)
Drug: Semaglutide

The primary purpose of this study is to compare the effect of mitapivat versus placebo on anemia in participants with alpha- or beta-non-transfusion...

Active, not recruiting
Non-Transfusion-dependent Alpha-Thalassemia
Non-Transfusion-dependent Beta-Thalassemia
Drug: Placebo Matching Mitapivat
Drug: Mitapivat
Locations recently updated

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Enrolling
Crohn's Disease
Biological: JNJ-78934804
Biological: Golimumab
Locations recently updated

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Enrolling
Atrial Fibrillation
Drug: Apixaban Placebo
Drug: Milvexian

A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following participants:* Participants rec...

Enrolling
Beta-thalassemia
Myelodysplastic Syndromes (MDS)
Drug: Luspatercept
Locations recently updated

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: Placebo
Drug: Upadacitinib (ABT-494)

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivek...

Begins enrollment this month
Acute Myocardial Infarction (AMI)
Cardiovascular Risk
Drug: Placebo
Drug: Ziltivekimab

This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults wit...

Active, not recruiting
Idiopathic Pulmonary Fibrosis
Drug: Placebo
Drug: Deupirfenidone

A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that...

Active, not recruiting
Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis
Drug: Pelabresib
Drug: Placebo

The TRACK trial is an investigator-initiated, multicentre, prospective, randomised, quadruple-blind (participant, healthcare provider, data collector...

Enrolling
Chronic Kidney Diseases
Dialysis-dependent Kidney Failure
Drug: Rivaroxaban 2.5 Mg Oral Tablet
Other: Placebo

The study is conducted in patients with functional dyspepsia or chronic gastritis. The purpose of this study is to:* assess whether the dose of Itopr...

Enrolling
Functional Dyspepsia
Drug: Itopride Hydrochloride 150 mg extended release tablets
Drug: Itopride Hydrochloride 50 mg film coated tablets
Locations recently updated

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Enrolling
Chronic Kidney Disease
Inflammation
Drug: Placebo (Ziltivekimab B)
Drug: Placebo (Ziltivekimab C)

Trial sponsors

Novo Nordisk logo
AbbVie logo
J
Allergan logo
Celgene logo
Boehringer Ingelheim logo
J
C
H
Abbott logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems